The new 6th edition of this respected management report is the essential reference work for everyone in the field. The report covers121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products. Over 1,500 pages analysing the structure, performance and research of more than 120 leading cancer drug development companies - now available.

Cancer continues to dominate industry research and investment as the search for really effective therapies hots up. The commercial rewards for companies that make significant breakthroughs in the cure or control of key cancers such as breast, ovarian, lung and prostate are considerable.

The application of biotechnology to the identification and development of drug candidates has seen a variety of novel paths pursued by a range of development companies.

For analysts, investors and pharmaceutical company executives, being able to readily and easily assess these companies, the research they are pursuing, products being developed, collaborators and financial performance/funding is key to understanding this sector of the market.

That is why the new 6th edition of this respected management report, Who's Developing What in New Cancer Drugs? is the essential reference work for everyone in the field. The report covers 121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:

Summary: At a glance review of agreements, products and R&D pipeline.
Overview: Background, technology and research techniques they have developed for drug discovery.
Agreements: Key details of who the company is collaborating with, and on what.
Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
Financial: An analysis of financial performance including P&L, R&D expenditure and funding.
Companies Analysed
Access Pharmaceuticals
Active Biotech
ADVENTRX Pharmaceuticals
AEterna Zentaris
Alchemia
Alfacell
Allos Therapeutics
Ambrilia Biopharma
Amgen
Angiogene Pharmaceuticals
AntiCancer
Antigenics
Antisense Pharma
Antisoma
ARIAD Pharmaceuticals
ARIUS Research
Ark Therapeutics
ArQule
Array BioPharma
AstraZeneca
Attenuon
AVAX Technologies
Bayer
Biogen Idec
Biomira
BioNumerik Pharmaceuticals
BioVex
Bristol-Myers Squibb
BTG International
Callisto Pharmaceuticals
Can-Fite BioPharma
CEL-SCI
Celgene
Cell Genesys
Cell Therapeutics
Cephalon
Clavis Pharma
Coley Pharmaceutical
Curagen Corporation
Cyclacel Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Dendreon
Eli Lilly
Endocyte
EntreMed
Enzon Pharmaceuticals
EpiCept
Exelixis
Favrille
Gamida Cell
Genentech
Genitope
Genmab
Genta
GenVec
Genzyme Oncology
Geron
GlaxoSmithKline
GPC Biotech
Hana Biosciences
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
ImmunoGen
Immunomedics
Introgen Therapeutics
Isis Pharmaceuticals
Keryx Biopharmaceuticals
Kirin Holdings Company
Kosan Biosciences
Kyowa Hakko Kogyo
Ligand Pharmaceuticals
Lorus Therapeutics
Marshall Edwards
Medarex
MediGene
Merck KGaA
MethylGene
MGI Pharma
Micromet Millennium Pharmaceuticals
NeoPharm
Northwest Biotherapeutics
Novacea
Novartis
OncoGenex Technologies
Oncolytics Biotech
Onyvax
Onyx Pharmaceuticals
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Panacea Pharmaceuticals
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaMar
PhotoCure
Progen Industries
Progenics Pharmaceuticals
Protherics
Quest PharmaTech
Roche
sanofi-aventis
Schering-Plough
Seattle Genetics
Spectrum Pharmaceuticals
SuperGen
Synta Pharmaceuticals
Tekmira Pharmaceuticals
Telik
TopoTarget
Transgene
Vical
Vion Pharmaceuticals
ViRexx Medical
Viventia Biotech
Wilex
YM Bioscience